These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 22698399)

  • 1. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
    Yang Y; Shaffer AL; Emre NC; Ceribelli M; Zhang M; Wright G; Xiao W; Powell J; Platig J; Kohlhammer H; Young RM; Zhao H; Yang Y; Xu W; Buggy JJ; Balasubramanian S; Mathews LA; Shinn P; Guha R; Ferrer M; Thomas C; Waldmann TA; Staudt LM
    Cancer Cell; 2012 Jun; 21(6):723-37. PubMed ID: 22698399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
    Solomon LA; Batista CR; DeKoter RP
    Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
    Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
    Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
    Ezell SA; Mayo M; Bihani T; Tepsuporn S; Wang S; Passino M; Grosskurth SE; Collins M; Parmentier J; Reimer C; Byth KF
    Oncotarget; 2014 Jul; 5(13):4990-5001. PubMed ID: 24970801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
    Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
    Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
    Lu L; Zhu F; Zhang M; Li Y; Drennan AC; Kimpara S; Rumball I; Selzer C; Cameron H; Kellicut A; Kelm A; Wang F; Waldmann TA; Rui L
    Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E498-E505. PubMed ID: 29295936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
    Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
    Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.
    Care MA; Cocco M; Laye JP; Barnes N; Huang Y; Wang M; Barrans S; Du M; Jack A; Westhead DR; Doody GM; Tooze RM
    Nucleic Acids Res; 2014 Jul; 42(12):7591-610. PubMed ID: 24875472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.
    Pulvino M; Chen L; Oleksyn D; Li J; Compitello G; Rossi R; Spence S; Balakrishnan V; Jordan C; Poligone B; Casulo C; Burack R; Shapiro JL; Bernstein S; Friedberg JW; Deshaies RJ; Land H; Zhao J
    Oncotarget; 2015 Jun; 6(17):14796-813. PubMed ID: 26142707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
    Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
    Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
    Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
    Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
    Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
    Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
    Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.